Filing Details

Accession Number:
0001225208-22-012182
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-02 16:32:01
Reporting Period:
2022-11-30
Accepted Time:
2022-12-02 16:32:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
200406 Johnson & Johnson JNJ Pharmaceutical Preparations (2834) 221024240
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1745936 Ashley Mcevoy One Johnson &Amp; Johnson Plaza
New Brunswick NJ 08933
Evp, Ww Chair, Medtech No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-30 73,323 $72.54 115,136 No 4 M Direct
Common Stock Disposition 2022-11-30 1,400 $176.09 113,736 No 4 S Direct
Common Stock Disposition 2022-11-30 71,923 $175.46 41,813 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (Right to Buy) Disposition 2022-11-30 73,323 $0.00 73,323 $72.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-01-17 2023-01-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,695 Indirect By 401k
Common Stock 300 Indirect By ESOP
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $176.050 to $176.115. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed in multiple trades at prices ranging from $175.040 to $176.010. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)
  4. Shares held by ESOP under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (10/31/2022)